At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers
U.S. Army Medical Research and Development Command·interventional·Posted Feb 10, 2006·Updated Jun 20, 2017
In Brief
A Phase 1 clinical trial evaluating D1ME100 (dengue-1 premembrane/envelope DNA vaccine) for Dengue. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesUnited States
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionDec 2006
Study CompletionApr 2009
TodayJul 2026
First PostedFeb 10, 2006
Enrollment StartJan 1, 2006
Primary CompletionDec 1, 2006
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.4 years ago
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)biological
IM injection delivered by Biojector